Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Recurrence × Radiosurgery × Clear all

Phase

Phase 2 5 Phase NA 3 Phase 4 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Squamous Cell Carcinoma of Head and Neck 1 Salivary Gland Neoplasms 1 Recurrence 1 Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 Head and Neck Neoplasms 1 Glioblastoma 1

Interventions

relmacabtagene autoleucel 2 fludarabine phosphate 2 fludarabine 2 Cytarabine 2 Brentuximab Vedotin 2 Antilymphocyte Serum 2 tocilizumab 1 sofosbuvir-velpatasvir drug combination 1 rasburicase 1 ledipasvir 1 entecavir 1 apatinib 1 aflibercept 1 acalabrutinib 1 Urate Oxidase 1 Trabectedin 1 Thiotepa 1 Tenofovir 1 Sofosbuvir 1 Rivaroxaban 1 Ribavirin 1 Radiotherapy 1 Radiosurgery 1 Pharmacokinetics 1 Mitomycin 1 Lamivudine 1 Granulocyte Colony-Stimulating Factor 1 Filgrastim 1 Ethiodized Oil 1 Epirubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05900908 2025-04-10

PATHWAyS

GT Medical Technologies, Inc.

Phase 4 Withdrawn

Glioblastoma, Neoplasm Metastasis, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡